Top 10 Companies in the Global Pharmaceutical Grade Microcrystalline Cellulose Market (2026): Market Leaders Driving Excipients Innovation

MARKET INSIGHTS

Global pharmaceutical grade microcrystalline cellulose market size was valued at USD 723.4 million in 2024. The market is projected to grow from USD 775.6 million in 2025 to USD 1,299.02 million by 2032, exhibiting a CAGR of 7.3% during the forecast period.

Pharmaceutical grade microcrystalline cellulose (MCC) is a purified, partially depolymerized cellulose produced through acid hydrolysis of alpha‑cellulose obtained from wood pulp or cotton fibers. It serves as a crucial excipient in drug formulations due to its excellent binding, disintegration, and compressibility properties, making it indispensable in tablet manufacturing. The product exists in various grades differentiated by particle size and density, with common types including PH‑101, PH‑102, and PH‑200.

The market growth is driven by increasing pharmaceutical production, particularly in emerging economies, and rising demand for direct compression technology in tablet manufacturing. Furthermore, the expanding generic drug market and advancements in modified‑release formulations are creating new opportunities. Key players like DuPont, JRS Pharma, and Roquette are investing in capacity expansions to meet growing demand. For instance, in Q1 2024, DuPont announced a USD 50 million investment to expand its MCC production capacity in the U.S., anticipating sustained market growth through 2030.

Global Pharmaceutical Grade Microcrystalline Cellulose Market – View in Detailed Research Report

🔟 1. DuPont

Headquarters: Wilmington, Delaware, USA
Key Offering: MCC PH‑101, PH‑102, PH‑200; advanced co‑processed grades

DuPont leverages its deep material‑science expertise to supply MCC that meets the strictest pharmacopeial standards. The company’s U.S. expansion of 50 million USD in 2024 underscores its commitment to sustaining high‑quality excipient output for the growing U.S. generics and specialty markets.

Sustainability & Growth Initiatives:

• Investing in renewable wood‑pulp sourcing to reduce carbon footprint
• Developing co‑processed excipients that enhance flow and compressibility
• Partnering with contract manufacturers to streamline direct‑compression workflows

9️⃣ 2. JRS Pharma

Headquarters: Berlin, Germany
Key Offering: MCC PH‑200; specialty grades for controlled‑release tablets

JRS Pharma’s focus on high‑purity MCC and its robust German production base positions it as a preferred supplier for European generics and innovator manufacturers seeking reliable excipient quality.

Sustainability & Growth Initiatives:

• Optimizing production energy use to achieve lower CO₂ emissions
• Expanding capacity in Eastern Europe to serve the growing market
• Collaborating with research institutes on next‑generation excipient formulations

8️⃣ 3. Roquette

Headquarters: Villeneuve‑Loubet, France
Key Offering: MCC PH‑101; specialty co‑processed excipients

Roquette’s long‑standing reputation for consistency and its investment in advanced purification technologies make it a trusted partner for pharmaceutical companies across Europe and beyond.

Sustainability & Growth Initiatives:

• Adopting circular bio‑economy principles in raw‑material sourcing
• Deploying state‑of‑the‑art GMP facilities to reduce waste
• Investing in digital quality‑management platforms

7️⃣ 4. Asahi Kasei

Headquarters: Tokyo, Japan
Key Offering: MCC PH‑102; high‑purity grades for biologics

Asahi Kasei’s presence in the Asia‑Pacific market is reinforced by its focus on high‑purity excipients that meet the stringent requirements of biologic drug developers.

Sustainability & Growth Initiatives:

• Integrating sustainable forestry certifications into supply chain
• Expanding R&D into excipient blends for high‑potency drugs
• Enhancing traceability through blockchain‑based batch tracking

6️⃣ 5. Mingtai

Headquarters: Beijing, China
Key Offering: MCC PH‑101, PH‑102; cost‑effective grades for Chinese generics

Mingtai’s rapid expansion in China’s domestic market aligns with the country’s push to strengthen local pharmaceutical manufacturing capabilities.

Sustainability & Growth Initiatives:

• Investing in high‑efficiency pulp‑processing plants
• Scaling production to meet the rising demand for generic drugs
• Implementing ISO 9001 and ISO 14001 certifications across facilities

5️⃣ 6. Accent Microcell

Headquarters: Bangalore, India
Key Offering: MCC PH‑200; specialty grades for nutraceuticals

Accent Microcell’s focus on cost‑effective manufacturing and its alignment with India’s growing nutraceutical sector positions it as a key regional player.

Sustainability & Growth Initiatives:

• Leveraging local cotton waste streams for cellulose sourcing
• Optimizing production to reduce water consumption
• Expanding distribution networks across South Asia

4️⃣ 7. Sigachi

Headquarters: Hyderabad, India
Key Offering: MCC PH‑101; high‑purity grades for biologics

Sigachi’s emphasis on high‑purity MCC supports the growing demand for biologics and advanced drug delivery systems in the Indian market.

Sustainability & Growth Initiatives:

• Adopting renewable energy sources for manufacturing
• Investing in digital process control to improve yield
• Collaborating with pharma partners on formulation development

3️⃣ 8. Wei Ming Pharmaceutical

Headquarters: Taipei, Taiwan
Key Offering: MCC PH‑102; specialty grades for oral solid dosage forms

Wei Ming’s strong focus on quality and compliance with USP, EP, and JP standards makes it a preferred supplier for manufacturers in East Asia.

Sustainability & Growth Initiatives:

• Implementing green manufacturing practices across plants
• Expanding capacity to meet regional demand for generics
• Enhancing supply‑chain transparency through traceability systems

2️⃣ 9. Anhui Sunhere Pharmaceutical

Headquarters: Hefei, China
Key Offering: MCC PH‑200; high‑purity grades for specialty drugs

Anhui Sunhere’s focus on high‑purity excipients aligns with China’s regulatory push for stricter quality controls.

Sustainability & Growth Initiatives:

• Optimizing pulp‑processing to reduce waste
• Investing in advanced purification technologies
• Expanding export capabilities to Southeast Asia

1️⃣ 10. Shandong Guangda

Headquarters: Jinan, China
Key Offering: MCC PH‑101; cost‑effective grades for generics

Shandong Guangda’s strategic location and cost‑efficient manufacturing make it a key supplier for the Chinese generic market.

Sustainability & Growth Initiatives:

• Adopting sustainable forestry certifications for raw materials
• Scaling production to meet the rising demand for tablets in China
• Implementing ISO 9001 and ISO 14001 standards across facilities

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/283390/global-pharmaceutical-grade-microcrystalline-cellulose-market

Get Full Report Here: https://www.24chemicalresearch.com/reports/283390/global-pharmaceutical-grade-microcrystalline-cellulose-market

🌍 Outlook: The Future of Pharmaceutical Grade Microcrystalline Cellulose Market

The global market for pharmaceutical grade microcrystalline cellulose is set to expand as the demand for solid dosage forms, particularly tablets, continues to rise. The increasing prevalence of chronic diseases, coupled with the growth of the generics sector in emerging economies, drives sustained consumption of MCC. Continued investment in capacity expansion by leading players and the adoption of advanced co‑processed excipients are expected to shape the market trajectory.

📈 Key Trends Shaping the Market

• Accelerated adoption of co‑processed MCC grades that enhance flowability and compressibility.
• Expanding biologics and high‑potency drug manufacturing demanding high‑purity excipients.
• Growing focus on sustainable sourcing of raw materials to meet environmental regulations.
• Digitalization of supply‑chain and quality‑management systems to ensure traceability and compliance.